Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
21/10/2013
21/10/2013
2012
|
Resumo |
Objective. To assess the efficacy and safety of pandemic 2009 influenza A (H1N1) in SLE under different therapeutic regimens. Methods. A total of 555 SLE patients and 170 healthy controls were vaccinated with a single dose of a non-adjuvanted preparation. According to current therapy, patients were initially classified as SLE No Therapy (n = 75) and SLE with Therapy (n = 480). Subsequent evaluations included groups under monotherapy: chloroquine (CQ) (n = 105), prednisone (PRED) epsilon 20 mg (n = 76), immunosuppressor (IS) (n = 95) and those with a combination of these drugs. Anti-H1N1 titres and seroconversion (SC) rate were evaluated at entry and 21 days post-vaccination. Results. The SLE with Therapy group had lower SC compared with healthy controls (59.0 vs 80.0%; P < 0.0001), whereas the SLE No Therapy group had equivalent SC (72 vs 80.0%; P = 0.18) compared with healthy controls. Further comparison revealed that the SC of SLE No Therapy (72%) was similar to the CQ group (69.5%; P = 0.75), but it was significantly reduced in PRED epsilon 20 mg (53.9%; P = 0.028), IS (55.7%; P = 0.035) and PRED epsilon 20 mg + IS (45.4%; P = 0.038). The concomitant use of CQ in each of these later regimens was associated with SC responses comparable with SLE No Therapy group (72%): PRED epsilon 20 mg + CQ (71.4%; P = 1.00), IS + CQ (65.2%; P = 0.54) and PRED epsilon 20 mg + IS + CQ (57.4%; P = 0.09). Conclusion. Pandemic influenza A H1N1/2009 vaccine response is diminished in SLE under immunosuppressive therapy and antimalarials seems to restore this immunogenicity. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2009/51897-5, 2010/10749-0] Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [303165/2008-1, 300248/2008-3, 301411/2009-3] Federico Foundation Federico Foundation Butantan Foundation Butantan Foundation |
Identificador |
RHEUMATOLOGY, OXFORD, v. 51, n. 6, supl. 4, Part 1-2, pp. 1061-1069, JUN, 2012 1462-0324 http://www.producao.usp.br/handle/BDPI/35177 10.1093/rheumatology/ker427 |
Idioma(s) |
eng |
Publicador |
OXFORD UNIV PRESS OXFORD |
Relação |
RHEUMATOLOGY |
Direitos |
closedAccess Copyright OXFORD UNIV PRESS |
Palavras-Chave | #SYSTEMIC LUPUS ERYTHEMATOSUS #VACCINE #INFECTION #INFLUENZA #ANTIMALARIALS #DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS #IMMUNOSUPPRESSIVE #H1N1 VACCINATION #IMMUNE RESPONSE #EFFICACY #PREVENTION #SYSTEMIC-LUPUS-ERYTHEMATOSUS #HUMORAL IMMUNE-RESPONSE #RHEUMATIC-DISEASES #MALARIA CHEMOPROPHYLAXIS #ANTIBODY-RESPONSE #IN-VIVO #SAFETY #CHLOROQUINE #IMMUNIZATION #RECOMMENDATIONS #RHEUMATOLOGY |
Tipo |
article original article publishedVersion |